Canadian Anticoagulant Percutaneous Coronary Intervention Registry
CAPCIR
Canadian Prospective, Observational Study on the Use of LMWH in the Setting of Percutaneous Coronary Intervention
1 other identifier
observational
747
1 country
1
Brief Summary
Advances in mechanical intervention (PCI) and anticoagulation therapy have been the cornerstone of treatment of patients with coronary artery disease. However, the large diversity of approaches to anticoagulation during PCI introduces gaps in knowledge regarding management of cardiac patients. As such, we have initiated a national PCI registry to elucidate anticoagulant choice, dosing strategies, case selection dynamics, and clinical outcomes in the Canadian health care environment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 28, 2008
CompletedStudy Start
First participant enrolled
February 1, 2008
CompletedFirst Posted
Study publicly available on registry
October 16, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2011
CompletedOctober 5, 2011
October 1, 2011
2.3 years
January 28, 2008
October 3, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Description of anticoagulant management during PCI and current practices of participating centres will be undertaken
in-hospital
Secondary Outcomes (3)
In-hospital safety outcomes including - major, minor bleeding, requirement for transfusion, death, myocardial infarction (or re-MI), myocardial ischemia requiring urgent revascularization, and major bleeding
in-hospital
In-hospital angiographic complications: no reflow, thrombus, occlusion of collateral branches, distal embolism, coronary dissection, acute closure of the culprit vessel
in-hospital
PCI-related resources utilization during the study period, including cost of PCI and its treatment (e.g. duration of hospital stay, drug costs, costs related to bleeding such as transfusions)
in-hospital
Study Arms (3)
A
Stable/elective PCI patients
B
NSTEMI PCI patients
C
STEMI PCI patients
Eligibility Criteria
UA, STEMI and NSTEMI ACS patients treated prior to PCI with LMWH and/or patients treated with LMWH during PCI i.e. in catheterization laboratory.
You may qualify if:
- or more years of age.
- Undergoing PCI during treatment with LMWH
- Provision of written and informed consent
You may not qualify if:
- Language, medical, or psychiatric barriers that preclude understanding of informed consent process.
- Patients in which the site investigator is unable to comply with completion of study documentation following PCI, i.e. patients with planned transfer to another hospital not participating in the registry.
- Enrollment in a clinical trial involving another anticoagulant agent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Alberta
Edmonton, Alberta, T6G 2B7, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
January 28, 2008
First Posted
October 16, 2008
Study Start
February 1, 2008
Primary Completion
June 1, 2010
Study Completion
September 1, 2011
Last Updated
October 5, 2011
Record last verified: 2011-10